Applied Therapeutics Inc
NASDAQ:APLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ningbo Ronbay New Energy Technology Co Ltd
SSE:688005
|
CN |
|
R
|
ReWay Group SpA
MIL:RWY
|
IT |
|
Suzhou Cheersson Precision Metal Forming Co Ltd
SZSE:002976
|
CN |
|
Bexcellent Group Holdings Ltd
HKEX:1775
|
HK |
|
Arjo AB (publ)
STO:ARJO B
|
SE |
|
R
|
Ram Ratna Wires Ltd
NSE:RAMRAT
|
IN |
|
Poonawalla Fincorp Ltd
NSE:POONAWALLA
|
IN |
Applied Therapeutics Inc
EPS (Diluted)
Applied Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Applied Therapeutics Inc
NASDAQ:APLT
|
EPS (Diluted)
$0
|
CAGR 3-Years
60%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Applied Therapeutics Inc
Glance View
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
See Also
What is Applied Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.1
USD
Based on the financial report for Sep 30, 2025, Applied Therapeutics Inc's EPS (Diluted) amounts to -0.1 USD.
What is Applied Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
49%
Over the last year, the EPS (Diluted) growth was 93%. The average annual EPS (Diluted) growth rates for Applied Therapeutics Inc have been 60% over the past three years , 49% over the past five years .
